A Phase 4 interventional study of Recombinant human growth hormone (r-hGH) in Dwarfism, Pituitary, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Per ClinicalTrials.gov, last updated 2014-02-13.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 9th largest by enrollment, is one of 3 that started in 2007, is one of 19 in phase 4, and was the 36th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Changchun GeneScience Pharmaceutical Co., Ltd.
Ages 6 mo–17 yrs
By country, each count listing its studies:
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 19
First in 1997; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 214 is above the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 66 across the 60 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 60 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
13 studies in Dwarfism, Pituitary by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 13 finished, 7 (54%) have results posted.
Among the 13 studies in Dwarfism, Pituitary by Merck KGaA, Darmstadt, Germany, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2007, is one of 6 in phase 4, and was the 9th registered.
Merck KGaA, Darmstadt, Germany’s Dwarfism, Pituitary studies by the year they started, since 2003.
2 of the studies testing Human Growth Hormone in Dwarfism, Pituitary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 13 in Dwarfism, Pituitary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, prospective, multicentric, non-comparative, non-randomized Phase IV interventional study in which subjects pre-diagnosed with Growth Hormone Deficiency (GHD) were treated for 4 weeks with Saizen to compare the response between GHD children born appropriate for gestational age (AGA) and those born small for gestation age (SGA) after 4 weeks of Saizen therapy.
The response to growth hormone (GH) treatment, short-term as well as long-term, displays considerable inter individual variability. This is particularly evident for the endpoint of paediatric GH administration, that is (i.e.) the growth response, which is pronounced in children who are affected by GHD. This is an open-label, multicentric study in which subjects pre-diagnosed with GHD were treated for 4 weeks with Saizen. Two hundred fourteen GHD evaluable pre-pubertal subjects were planned to be recruited in approximately 9 sites in China. Demographic data, medical history, tanner stage, physical examination, body weight, height, bone age measurement, body mass index, review of baseline medications and procedures and blood sampling were performed at baseline visit, end of treatment visit (week 4) and at 4 week follow-up visit.
OBJECTIVES
Primary objective:
Secondary Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit \[IU\]/kg body weight) per day by subcutaneous injection.
Also known as: Saizen
Change From Baseline in Serum Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) Levels at Week 4
Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was calculated as logarithm (log) 10 actual value of IGF-1 - log 10 (mean reference value of IGF-1) divided by log10 reference standard deviation of IGF-1.
Time frame: Baseline and Week 4
Change From Baseline in Insulin Like Growth Factor Binding Protein-3 (IGFBP-3) Levels at Week 4
Time frame: Baseline and Week 4
Change From Baseline in Fasting Glucose at Week 4
Time frame: Baseline and Week 4
Change From Baseline in Fasting Insulin at Week 4
Time frame: Baseline and Week 4
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) Test at Week 4
HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter \[pmol/L\]) \* fasting plasma glucose (millimole/liter \[mmol/L\]) divided by 22.5.
Time frame: Baseline and Week 4
Change From Baseline in Lipid Profile at Week 4
Total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides levels were evaluated.
Time frame: Baseline and Week 4
| Milestone | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| Started | 183 | 30 |
| Treated | 175 | 30 |
| Completed | 169 | 29 |
| Not completed | 14 | 1 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Other | 3 | 0 |
| Withdrew: Randomized but not treated | 8 | 0 |
Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) was calculated as logarithm (log) 10 actual value of IGF-1 - log 10 (mean reference value of IGF-1) divided by log10 reference standard deviation of IGF-1.
| nanogram/millilter (ng/mL) | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| Baseline | -2.04 ± 2.341 | -2.22 ± 2.390 |
| Change at Week 4 | 1.38 ± 1.358 | 0.85 ± 1.257 |
| microgram/mL (mcg/mL) | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| Baseline | 3.16 ± 1.386 | 2.57 ± 1.525 |
| Change at Week 4 | 0.58 ± 0.869 | 0.51 ± 0.805 |
| millimole/liter (mmol/L) | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| Baseline | 4.83 ± 0.471 | 4.46 ± 1.106 |
| Change at Week 4 | 0.17 ± 0.578 | 0.22 ± 0.886 |
| picomole/L (pmol/L) | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| Baseline | 36.17 ± 74.575 | 23.58 ± 14.892 |
| Change at Week 4 | 10.08 ± 81.674 | 12.04 ± 32.389 |
HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter \[pmol/L\]) \* fasting plasma glucose (millimole/liter \[mmol/L\]) divided by 22.5.
| pmol/L*mmol/L | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| Baseline | 7.91 ± 15.662 | 5.06 ± 3.290 |
| Change at Week 4 | 2.96 ± 18.458 | 2.48 ± 6.527 |
Total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglycerides levels were evaluated.
| mmol/L | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| Baseline (Total Cholesterol) | 4.16 ± 0.752 | 4.22 ± 0.833 |
| Baseline (HDL-Cholesterol) | 1.56 ± 0.452 | 1.59 ± 0.443 |
| Baseline (LDL-Cholesterol) | 2.18 ± 0.672 | 2.19 ± 0.709 |
| Baseline (Triglycerides) | 0.99 ± 0.527 | 1.02 ± 0.638 |
| Change at Week 4 (Total Cholesterol) | -0.28 ± 0.601 | -0.03 ± 0.612 |
| Change at Week 4 (HDL-Cholesterol) | -0.10 ± 0.317 | 0.02 ± 0.329 |
| Change at Week 4 (LDL-Cholesterol) | -0.24 ± 0.546 | 0.02 ± 0.502 |
| Change at Week 4 (Triglycerides) | 0.12 ± 0.551 | -0.09 ± 0.831 |
Collected over Adverse Events (AEs) are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until 4 weeks post drug administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Appropriate for Gestational Age (AGA) | — | 1/175 (0.6%) | 27/175 (15.4%) |
| Small for Gestational Age (SGA) | — | 0/30 (0%) | 3/30 (10%) |
| Event | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| AppendicitisInfections and infestations | 1/175 | 0/30 |
| Event | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) |
|---|---|---|
| HyperhidrosisGeneral disorders | 0/175 | 1/30 |
| PyrexiaGeneral disorders | 5/175 | 1/30 |
| AnorexiaMetabolism and nutrition disorders | 0/175 | 1/30 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 1/175 | 1/30 |
| Upper Respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders | 4/175 | 0/30 |
| HeadacheNervous system disorders | 3/175 | 0/30 |
| Ocular HypertensionEye disorders | 2/175 | 0/30 |
| VomitingGastrointestinal disorders | 2/175 | 0/30 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 2/175 | 0/30 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 2/175 | 0/30 |
| Age, Continuous(years) | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) | Total |
|---|---|---|---|
| Mean | 10.52 ± 3.844 | 9.39 ± 4.349 | 10.35 ± 3.931 |
| Sex: Female, Male(Participants) | Appropriate for Gestational Age (AGA) | Small for Gestational Age (SGA) | Total |
|---|---|---|---|
| Female | 46 | 6 | 52 |
| Male | 129 | 24 | 153 |
No study locations are listed for this record.
The record gives a start of Mar 2007, a primary completion of Sep 2008 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Merck KGaA, Darmstadt, Germany →